US biotech firm RegenxBio has signed a non-exclusive global licence deal with Pfizer, allowing the drug manufacturer to use its NAV AAV9 vector in the development of a possible gene therapy for Friedreich’s ataxia. The condition affects around one in one US people and can lead to various complications, diabetes and cardiomyopathy. RegenxBio recently signed an exclusive deal with Neurimmune to develop novel AAV gene therapies, using NAV vectors for chronic neurodegenerative diseases.
US biotech firm RegenxBio has signed a non-exclusive global licence deal with Pfizer, allowing the drug manufacturer to use its NAV AAV9 vector in the development of a possible gene therapy for Friedreich’s ataxia. The condition affects around one in 50,000 US people and can lead to various complications, diabetes and cardiomyopathy. RegenxBio recently signed an exclusive deal with Neurimmune to develop novel AAV gene therapies, using NAV vectors for chronic neurodegenerative diseases.